ABSTRACT INTRODUCTION
Mucormycosis is an uncommon opportunistic infection, which represents the third most common angio-invasive fungal infection after candidiasis and aspergillosis and is considered as one of the most important medical complications in immunocompromised patients [1, 2] .
Even though it is extremely rare, it has been reported from all corners of the world [1, 3] . The majority of cases reported were either isolated communications or small, retrospective series [4] . Management of this devastating infection is still big challenge and is based on different strategies which include a rapid diagnosis, reduction of risk factors and rapid and aggressive antifungal agents with or without surgical debridement [5] . 
MATERIALS AND METHODS
We report 14 cases of Mucormycosis retrospectively reviewing medical records of such patients and have made attempt to define clinical features, risk factors, diagnosis and treatment of such patients.
RESULTS
Our series compromised of 14 cases seen over a period of 5 years. Data studied were patient age, gender, underlying disorders, clinical features, risk factors, diagnostic procedures and treatment including side effects and outcome. Microbiological studies were performed on tissue biopsies.
Samples were examined microscopically in a 20% KOH mount and fungal culture was done in most cases. Histological studies included paraffin embedded H & E, PAS and methenamine silver stained slides.
Statistical methods:
Descriptive analyses were used to study the parameters. Microsoft word and excel have been used to generate the graphs and tables.
The study group consisted of 10 males and 4 females aged 20-70 years (mean 50 years). Almost all patients except one had at least one recognised underlying disorder ( 11 patients were treated with amphotericin B in the doses ranging from 0.5 -1.0 mg/kg up to a total of 2.6 grams, and duration of the treatment varied from 1 -31 days. Incidence and severity of adverse effects of treatment are recorded in table 1. Reaction varied from mild to severe and was intolerable in 2 cases. These patients were treated with liposomal form of the drugAmbisome. 07 cases had hypokalemia and 02 cases had renal dysfunction. 
DISCUSSION
Mucormycosis is a devastating infection of immunocompromised hosts. The different forms of mucormycosis are rhino-orbital-cerebral, pulmonary, disseminated, cutaneous, gastrointestinal and miscellaneous [6] [7] [8] .
The mucoraceae are ubiquitous in nature [6] [7] [8] . This fungi gain entry to the body through the respiratory tract. They have affinity for arteries and grow along the internal elastic lamina, causing thrombosis and infarction. Progression of the disease from the nose and sinuses is either direct or leads to the vascular occlusion of the orbital contents. Intracranial involvement occurs also from the invasion by the way of the superior orbital fissure, ophthalmic vessels and cribriform plate, through the carotid artery, or possibly via a perineural route.
Due to the rarity of this infection, it is difficult to calculate accurately its incidence. In 2011 Mignogna et.al [5] reported in their study the annual incidence of mucormycosis in United States is approximately 500 cases per year.
The mean age of the patients was 50 years in our study. Talmi et.al [4] in their study reported mean age of the patients was 50 years. Commonly, Mucormycosis has shown an equal sex distribution. But in our there is slightly male predominance with ratio of male: female is 2.5:1.
Uncontrolled diabetes mellitus was the most common underlying predisposing disease in our series. While Talmi et.al [4] reported hematological malignancies as most common underlying disease.
Orbital and nasal findings are the most common presenting clinical features. Orbital involvement ranges from 58 to 100% of cases in our series. Similar findings were also observed by Talmi et.al [4] in their study (66-100%). Orbital symptoms include loss of function of the 2 nd , 3 rd , and 6 th cranial nerves with proptosis, ptosis, Chemosis, orbital pain, central retinal artery occlusion, conjunctival hyperaemia, dilated pupil and visual loss. Invasion of the eye globe is uncommon and was noted in only one of our cases.
Cultures were positive in 8 of 14 our cases, of which one case had mixed fungal infections. Talmi et.al reported similar findings in their study. Rhizopus was the most common infective agent in our study.
The treatment of Mucormycosis is mainly medical treatment with amphotericin B (amph B) and surgical debridement. 11 received the treatment, 8 were treated with conventional amph B and 3 were treated with liposomal amph B and it is not widely used because of its cost.
CONCLUSION
Recognised side effects of amph B noted in our study are fever, chills, headache, nausea, vomiting, thromboplebitis, hypokalemia and azotemia.
Survival in mucormycosis patients dependent on multiple factors and early initiation of treatment is an important element. More than 60% of the patients survived in our study. Mucormycosis is a rare opportunistic fungal infection with rapidly progressive and fulminant course with often fatal outcome. A strong suspicion, prompt diagnosis with pathological confirmation and aggressive surgical treatment gives a better outcome.
